Asia Pacific Nifedipine Market Size, Share & Trends Analysis Report By Type (Nifedipine Controlled-Release Tablets, Nifedipine Extended Action Tablets), By Application (Primary Pulmonary Hypertension, Heart Failure, Raynaud’s Syndrome, Cephalalgia, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), By Region (North America, Asia-Pacific, Europe, Latin America, The Middle East and Africa) and By Country(China, Korea, Japan, India, Australia, Taiwan, South East Asia, Rest of Asia-Pacific) Forecasts, 2022-2030

Market Overview

Nifedipine is a calcium channel blocker, meaning it blocks calcium from passing through the walls of the arteries. High blood pressure, arrhythmias, and angina are all treated with nifedipine. Other therapeutic uses include ryanoids syndrome, cephalalgia, and other disorders of the same nature. Growth in the senior population, healthcare spending, the rise of chronic illnesses such as heart failure, arrhythmias, and hypertension, and healthcare awareness are all driving the market. Government regulations and unfavourable pharmacological repercussions such as hypotension, stomach ulcers, and congestive heart failure, on the other hand, stifle market expansion. R&D operations are expected to yield new development opportunities. Dihydropyridine calcium channel blockers, such as nitrendipine and nisoldipine, are used to treat high blood pressure. Premature labour has been more common in recent years, driving up demand for the medications mentioned above. Tocolytics, which function by inhibiting muscle contractions, are used to treat premature labour. Preemies are also protected from developing health problems as a result of their early birth with nifedipine. In 2020, the global nifedipine market was valued at USD 856.66 million, and by 2029, it is predicted to be worth USD 1,792.36 million, representing an annual growth rate of 8.49% (CAGR).

The Asia Pacific Nifedipine market size is expected to reach a valuation of USD 440.96 million by 2030, increasing at a rate of 8.7 % CAGR during the forecast period (2022–2030). During the forecast period, Asia-Pacific is predicted to increase at a high rate. This growth is attributable to an increment in chronic diseases as a result of an ageing population, especially in countries like India and China, as well as the refinement of healthcare infrastructure as governments invest vast sums of money in development.

Market Dynamics

Market Drivers

• Increasing Hypertension in the region: As the population ages and the prevalence of obesity and diabetes rises across Asia, the overall number of individuals with hypertension is expected to rise in the coming decades. With 4.3 billion people and a rapid growth rate, Asia is the world's largest and most populated continent, housing 60% of the world's current human population. As a result, the population suffering from hypertension is very vast, implying that demand for Nifedipine will certainly expand in the region.

• Huge Geriatric Population in Asia: By the middle of the century, Asia's old population is expected to reach approximately 923 million people. As a result, the region is on path to becoming one of the world's oldest in the coming decades. In general, Asian governments are unprepared for this massive upheaval, which will have far-reaching social and economic effects. The medical sector will need to prepare for the health difficulties that may arise as a result of the region's large senior population, and so nifedipine demand is expected to rise in the coming years.

Market Restraints

• Availability of Substitutes: Nifedipine, a dihydropyridine calcium channel blocker, was once one of the most widely used hypertension medications, but safety and tolerability concerns, as well as the introduction of new classes of antihypertensive medications and a growing body of data showing the mortality benefit of other classes, caused a drop in demand and hence this is a significant restraint in the growth of market apart from the fact that it also has some side effects associated with it.

Asia Pacific Nifedipine Market Opportunities

• Increasing Nifedipine Demand in Developing Countries to Attract Market Growth Opportunities: To Attract Market Growth Opportunities, Increase Nifedipine Demand in Developing Countries: In emerging Asian Pacific economies such as China, India and Japan, factors such as an increase in the incidence and prevalence of target diseases such as cardiovascular disease, preterm labour, and Raynaud's syndrome, as well as a large patient population and expanding healthcare infrastructure, are expected to propel market growth. As a result of increased efforts by major market participants and a growing elderly population base in emerging countries at high risk of catching target diseases, the Asian Pacific area will see significant demand in the future years.

Regional Analysis

By 2030, the Asia Pacific Nifedipine market is estimated to be worth USD 440.96 million, with a growth rate of 8.7% over the forecast period (2022–2030). Asia-Pacific is expected to grow at a rapid pace during the forecast period. This rise is due to a growth in chronic diseases as a result of an ageing population, especially in countries like India and China, as well as the refinement of healthcare infrastructure as governments invest large quantities of money in development.

Furthermore, favourable government assistance would result in market expansion. For example, by the end of 2025, India's National Health Policy aimed to cut 25% of premature deaths from cardiovascular diseases by screening and treating more than 80% of hypertension individuals. Furthermore, the Rastriya Arogya Nidhi (RAN) scheme provides financial support to patients who are below the poverty line; such activities help to enhance market demand. Furthermore, a significant player in the market, GlaxoSmithKline Plc (GSK), has decided to invest USD 1 billion in its Indian pharmaceutical unit, counting on growing demand in emerging markets while sales in established markets stagnate due to a wave of patent expirations. GSK expects to invest around USD 2 billion in two publicly traded Indian companies over the next year as part of the current India agreement, the company's highest incremental investment in any country during that time.

Cardiovascular disorders are becoming more common in China, causing nearly 4 million deaths each year. According to the findings, each of the main modifiable risk factors for cardiovascular disease—high systolic blood pressure, high LDL cholesterol, cigarette smoking, high BMI, and high fasting plasma glucose—is responsible for an increase in sickness and this has increased the demand for drugs and Nifedipine in the region.

In Japan, 43 million people are hypertensive, yet about half of them are treated, and only approximately a quarter of them are kept within the target blood pressure (BP) range of 140/90 mm Hg. Hypertension is one of the major causes of death in Japan, second only to smoking, due to the vast number of hypertensive people and low control rates, rising the demand for the Nifedipine in the region.

Segmental Analysis

Nifedipine controlled-release tablets and nifedipine extended-action tablets are the two types of nifedipine pills. Nifedipine controlled-release tablets had the most market share in 2021. This significant increase can be attributed to rising rates of hypertension and heart failure, the use of cutting-edge technology in pharmaceutical research, more funding from the government and international organisations, and increased public awareness about the importance of preventative treatment.

The portion is separated into primary pulmonary hypertension, heart failure, Raynaud's illness, cephalalgia, and others depending on the application. In 2021, the most prevalent cause of pulmonary hypertension was primary pulmonary hypertension. Obesity, poor dietary habits, excessive junk food intake, a lack of exercise, a rise in smoking and alcohol usage among the younger generation, and stress are all factors. This field is likely to be driven by increased government and private sector efforts, as well as concrete programmes for the development of new drugs to treat hypertension and diabetes.

The Asian Pacific nifedipine market is made up of hospital pharmacies, retail pharmacies, and other distribution channels. Hospital pharmacies dominated the regional market in 2020, and the market is expected to develop at a faster CAGR during the forecast period.

Impact of covid-19

The automotive industry is critical to the economy's growth. However, during the second and third quarters of 2020, the COVID-19 outbreak impacted the whole automotive supply chain, affecting new car sales in FY 2020.

South America is most affected by COVID-19, with Brazil leading the way, followed by Ecuador, Chile, Peru, and Argentina. South America's government (SAM) has taken a number of steps to protect its citizens and stem the spread of COVID-19. South America is expected to have fewer export revenues as commodity prices fall and export volumes fall, particularly to China, Europe, and the United States, which are all significant trading partners. The manufacturing industry, especially automotive manufacturing, has been damaged by containment measures in various South American countries. Due to the pandemic, major automotive manufacturers have also temporarily halted manufacturing in the region as a cost-cutting move. Furthermore, the automobile disc brake industry has been significantly affected in 2020 due to a lack of raw materials and supply chain disruption.

The Automotive Brake System control module of a vehicle is meant to alert the driver with a warning light if the system fails. The module itself is rarely defective; instead, the sensors or the wiring to the sensors are frequently defective. The most typical cause of dysfunction is when the Automotive Brake System is contaminated with particles or metal shavings. There is no signal continuity when sensor wiring is destroyed. Brake fluid becomes contaminated in corrosive situations, and the hydraulic unit fails to function.

Recent Developments

• By the end of 2025, India's National Health Policy aimed to prevent 25% of premature deaths from cardiovascular illnesses by screening and treating more than 80% of hypertension individuals. In addition, the Rastriya Arogya Nidhi (RAN) scheme provides financial support to patients who are poor.